Editors: Cecilia C. S. Yeung, Howard M. Shulman

2019

In 45 years, HSCT has emerged from a last-ditch experimental effort to cure hematologic malignancies into an established treatment with hundreds of transplant centers throughout the world. Despite the numerous technological advances leading to successful outcomes, GVHD with its associated immunodeficiency and infectious vulnerability remains the leading cause of non-relapse mortality.